

Fig. 7. Reproduction of HCV life cycle in OL8c and ORL8c cells. (A) Flow chart of experiments on HCVcc infection. A time schedule for HCVcc infection and sampling is shown. IF1d7-sup refers to the supernatant of the first-infected cells at 7 days p.i. IF2d7 refers to the secondly infected cells at 7 days p.i. (B) Production of infectious HCV from HCVcc-infected OL8c and OL11c cells. OL8c or OL11c cells were infected with HCVcc produced from RSc cells, and each supernatant at 7 days p.i. (IF1d7-sup) was used for inoculation to OL8c, OL11c, or RSc cells. Western blot analysis was performed to detect HCV core protein in OL8c or OL11c cells at 8 days p.i. (IF2d8). The supernatant (IF2d8-sup) from RSc cells at 8 days p.i. was used for further inoculation to OL8c or OL11c cells. Western blot analysis was performed for the detection of HCV core protein in OL8c or OL11c cells at 8 days p.i. (IF3d8). (C) HCVcc produced from OL8c cells is infectious to OL8c cells. The supernatants (IF1d7-sup) described in (B) were used for inoculation to OL8c and RSc cells. Li23 cells were used as negative controls. Western blot analysis was performed to detect HCV core protein in OL8c, RSc, or Li23 cells at 27 days p.i. (IF2d27). (D) Persistent production of infectious HCVcc from ORL8c cells. ORL8c or ORL11c cells were infected with HCVcc produced from RSc cells, and each supernatant at 7 days p.i. (IF1d7-sup) was used for inoculation to ORL8c or ORL11c cells. RSc cells were used as positive controls. Western blot analysis was performed to detect HCV core protein in ORL8c or ORL11c cells at 7, 14, 21, and 30 days p.i. (IF2). HCV core protein in RSc cells at 7 and 14 days p.i. was also detected by Western blot analysis. (E) Secretion of HCV core protein in culture supernatant. The culture supernatants (IF2d7-, IF2d14-, and IF2d22-sup) of ORL8c or RSc cells were used to determine the levels of core protein by enzyme-linked immunosorbent assay. Experiments were performed in triplicate. (F) Levels of HCV RNA in HCVcc-infected cells. The levels of intracellular HCV RNAs of ORL8c or RSc cells (IF2d7, IF2d14, and IF2d22) were determined by quantitative RT-PCR. Experiments were performed in triplicate. (G) Expression levels of CD81, SR-BI, Claudin-1, and Occludin among RSc, ORL8c, and ORL11c cells. RNA preparation and RT-PCR were performed as described in Fig. 3B. (H) Immunofluorescence analysis of HCVcc-infected cells. ORL8c or RSc cells (IF2d7) were processed and stained with anti-core, anti-NS5B, and anti-dsRNA antibodies and Cy2-conjugated secondary antibody. Mock-infected ORL8c cells served as negative controls. Bar, 20 μm.

2005), and various Li23-derived cell lines obtained in this study (Supplemental Table 2). A flow chart of the expression procedure is shown in Fig. 7A.

Since we detected the transient expression of HCV-JFH1 RNA in OL8c and OL11c cells (Supplemental Fig. 4A), we examined the susceptibility of OL1c, OL2c, OL3c, OL4c, OL8c, OL11c, or OL14c cells to cell culture-generated HCV-JFH1 (HCVcc) produced from HuH-7-derived RSc cells that HCVcc could infect and efficiently replicate (Ariumi et al., 2007, 2008; Kuroki et al., 2009). At 16 days post-infection (p.i.), the core protein was detected in OL2c, OL3c, OL8c, OL11c, and OL14c cells, but not in OL1c and OL4c cells (Supplemental Fig. 4B), indicating that most OLc series cells exhibit good susceptibility to HCVcc. In this context, the supernatant (IF1d7-sup) of HCVcc-infected OL8c or OL11c cells at 7 days p.i. was inoculated to naïve OL8c or OL11c cells; however, we failed to detect the core protein in the cells (IF2d8) at 8 days p.i. (Fig. 7B). However, when the supernatant (IF2d8-sup) of IF1d7-sup-inoculated RSc cells at 8 days p.i. was inoculated to naïve OL8c or OL11c cells, core expression was strongly detected in either case at 8 days p.i. (IF3d8) (Fig. 7B). This suggested that small amount of infectious HCV was produced from OL8c or OL11c cells. Accordingly, the expression of core protein was detected in IF1d7-sup-inoculated OL8c cells, but not in OL11c cells, at 27 days p.i. (IF2d27) (Fig. 7C), indicating that OL8c-derived HCVcc may infect and replicate in naïve OL8c cells. This finding leads to the assumption that ORL8c or ORL11c cells are better than OL8c cells, because ORL8c and ORL11c cells are derived from luciferase reporter full-length HCV RNA-replicating cells (ORL8 and ORL11), and because they each have a more permissible environment for HCV RNA replication. To test this hypothesis, RSc-derived HCVcc was commonly used in order to avoid the issue of uncertain efficiency of RNA transfection to RSc, ORL8c, or ORL11c cells. RSc-derived HCVcc was inoculated to naïve RSc, ORL8c, or ORL11c cells; and RSc, ORL8c, or ORL11c-derived IF1d7-sup was further inoculated to naïve RSc, ORL8c, or ORL11c cells. Expectedly, core expression in the ORL8c cells inoculated with ORL8c-derived IF1d7-sup was strongly detected until at least 30 days p.i. (IF2d30) (Fig. 7D). The level of core protein in the ORL8c cells was equivalent to that in the RSc cells inoculated with RSc, ORL8c, or ORL11c-derived IF1d7-sup (Fig. 7D). Regarding the NS5B expression, similar results were obtained (data not shown). These results suggest that HCV production in ORL8c cells is comparable to that in RSc cells. In contrast, core protein was not detected in ORL11c cells inoculated with ORL11c-derived IF1d7-sup (Fig. 7D). The core protein released into the culture supernatants (IF2d7-, IF2d14-, and IF2d22-sup) of HCVcc-infected ORL8c cells was persistently detected, although at somewhat lower levels than in the RSc cells (Fig. 7E). The level of intracellular HCV RNA in the ORL8c cells was $>10^7$ copies/μg total RNA at IF2d14; this is also somewhat lower than in the RSc cells (Fig. 7F). However, RT-PCR analysis revealed that the expression levels of HCV entry factors (CD81, SR-BI, Claudin-1, and Occuldin) were comparable among HuH-7, RSc, Li23, ORL8c, and ORL11c cells (Fig. 7G). Immunofluorescence analysis showed that the staining levels of dsRNA and HCV proteins were also comparable between HCVcc-infected ORL8c and RSc cells (IF2d7) (Fig. 7H). Colocalization of lipid droplet and HCV core protein was also observed in HCVcc-infected ORL8c and RSc cells (Supplemental Fig. 5), as previously reported (Miyanari et al., 2007). In summary, we demonstrated that ORL8c cells persistently supported the HCV life cycle.

4. Discussion

In this study, we found that human hepatoma Li23-derived cells possess the environments needed for robust genome-length HCV RNA replication and persistent production of infectious HCV. Using Li23-derived cell lines, we developed subgenomic and genome-length HCV RNA replication systems, drug assay systems, and a persistent HCV production system, which correspond to the counterparts of those using HuH-7-derived cell lines (Supplemental Table 2). It is noteworthy that the ORL8c cells cured from ORL8 cells, which were selected by the indicator of HCV RNA replication, showed good potential for producing HCV-JFH1. This finding suggests that the host factors required for robust HCV RNA replication – rather than those for HCV infection or reformation – are key determinants for reproducing the HCV life cycle in cell culture. In fact, we observed similar expression levels of the HCV entry factors between Li23- and HuH-7-derived cells. Therefore, such host factors might be commonly expressed in both ORL8c and RSc cells (Ariumi et al., 2007, 2008; Kuroki et al., 2009).

Our microarray analysis clearly demonstrated that OL8 and OL11 cell lines established in this study were not of HuH-7 cell origin, and revealed that Li23-derived cells possessed rather different expression profiles from those in HuH-7-derived cells (Fig. 3B), although similar liver-specific gene expression profiles were observed in both cell lineages (Fig. 3A). In addition, this analysis revealed that at least OL8 and OL11 cells possessed characteristic expression profiles of the parental Li23 cells, as Oc and OAc cells also showed the HuH-7-type expression profile. Therefore, further comparative studies on the mechanism(s) of HCV proliferation using Li23- and HuH-7-derived cell lines (e.g. ORL8c vs. RSc) may identify new host factor(s) required for efficient HCV proliferation.

A specific combination of adaptive mutations (Q1112R, K1609E, and S2200R) (Abe et al., 2007) is also a key determinant with which to find the Li23 cell line. Until the finding of such a combination of adaptive mutations, we had failed to establish any non-HuH-7-derived cells harboring the HCV replicon. Although it remains unclear what mechanism underlies these adaptive mutations that enhance HCV RNA replication, these mutations might be useful for the development HCV RNA replication systems of various HCV strains.

ORL8 and ORL11 assay systems might become important tools for evaluating or screening anti-HCV reagents, because these assay systems were frequently more sensitive to anti-HCV reagents than the HuH-7-derived OR6 assay system. However, the fact that the ORL8 and ORL11 assays were each more sensitive than the OR6 assay may be due to the fact that OR6 has a higher level of HCV RNA replication than ORL8 and ORL11 cells. Recently, we developed HCV replicon reporter assay systems using four genotype 1b HCV strains (1B-4, KAH5, O, and 1B-5), and found diverse sensitivities against various anti-HCV reagents among the replicons (Nishimura et al., 2009). In that study, we demonstrated that the sensitivities to anti-HCV reagents were not dependent on the replication levels of HCV RNA, and suggested that factor(s) other than the HCV RNA level are involved in conferring sensitivities to anti-HCV reagents including IFN-α (Nishimura et al., 2009). Therefore, the practical use of HuH-7- and Li23-derived assay systems would be very effective for accurately evaluating anti-HCV activity.

Finally, the most important feature of this report is that we were able to persistently produce infectious HCVcc using ORL8c cells. ORL8c-produced HCVcc would be very useful not only for verification of data obtained from HuH-7-derived cells but also for obtaining a variety of new information about the HCV life cycle.

Acknowledgments

We thank Takashi Nakamura and Atsumi Morishita for their technical assistance. We also thank S. Hirohashi, M. Namba, and D. Trono for Li21, Li24, OUMS29, IHH10.3, and IHH12 cell lines. This

2005), and various Li23-derived cell lines obtained in this study (Supplemental Table 2). A flow chart of the expression procedure is shown in Fig. 7A.

Since we detected the transient expression of HCV-JFH1 RNA in OL8c and OL11c cells (Supplemental Fig. 4A), we examined the susceptibility of OL1c, OL2c, OL3c, OL4c, OL8c, OL11c, or OL14c cells to cell culture-generated HCV-JFH1 (HCVcc) produced from HuH-7-derived RSc cells that HCVcc could infect and efficiently replicate (Ariumi et al., 2007, 2008; Kuroki et al., 2009). At 16 days post-infection (p.i.), the core protein was detected in OL2c, OL3c, OL8c, OL11c, and OL14c cells, but not in OL1c and OL4c cells (Supplemental Fig. 4B), indicating that most OLc series cells exhibit good susceptibility to HCVcc. In this context, the supernatant (IF1d7-sup) of HCVcc-infected OL8c or OL11c cells at 7 days p.i. was inoculated to naïve OL8c or OL11c cells; however, we failed to detect the core protein in the cells (IF2d8) at 8 days p.i. (Fig. 7B). However, when the supernatant (IF2d8-sup) of IF1d7-sup-inoculated RSc cells at 8 days p.i. was inoculated to naïve OL8c or OL11c cells, core expression was strongly detected in either case at 8 days p.i. (IF3d8) (Fig. 7B). This suggested that small amount of infectious HCV was produced from OL8c or OL11c cells. Accordingly, the expression of core protein was detected in IF1d7-sup-inoculated OL8c cells, but not in OL11c cells, at 27 days p.i. (IF2d27) (Fig. 7C), indicating that OL8c-derived HCVcc may infect and replicate in naïve OL8c cells. This finding leads to the assumption that ORL8c or ORL11c cells are better than OL8c cells, because ORL8c and ORL11c cells are derived from luciferase reporter full-length HCV RNA-replicating cells (ORL8 and ORL11), and because they each have a more permissible environment for HCV RNA replication. To test this hypothesis, RSc-derived HCVcc was commonly used in order to avoid the issue of uncertain efficiency of RNA transfection to RSc, ORL8c, or ORL11c cells. RSc-derived HCVcc was inoculated to naïve RSc, ORL8c, or ORL11c cells; and RSc, ORL8c, or ORL11c-derived IF1d7-sup was further inoculated to naïve RSc, ORL8c, or ORL11c cells. Expectedly, core expression in the ORL8c cells inoculated with ORL8c-derived IF1d7-sup was strongly detected until at least 30 days p.i. (IF2d30) (Fig. 7D). The level of core protein in the ORL8c cells was equivalent to that in the RSc cells inoculated with RSc, ORL8c, or ORL11c-derived IF1d7-sup (Fig. 7D). Regarding the NS5B expression, similar results were obtained (data not shown). These results suggest that HCV production in ORL8c cells is comparable to that in RSc cells. In contrast, core protein was not detected in ORL11c cells inoculated with ORL11c-derived IF1d7-sup (Fig. 7D). The core protein released into the culture supernatants (IF2d7-, IF2d14-, and IF2d22-sup) of HCVcc-infected ORL8c cells was persistently detected, although at somewhat lower levels than in the RSc cells (Fig. 7E). The level of intracellular HCV RNA in the ORL8c cells was $>10^7$ copies/μg total RNA at IF2d14; this is also somewhat lower than in the RSc cells (Fig. 7F). However, RT-PCR analysis revealed that the expression levels of HCV entry factors (CD81, SR-BI, Claudin-1, and Occuldin) were comparable among HuH-7, RSc, Li23, ORL8c, and ORL11c cells (Fig. 7G). Immunofluorescence analysis showed that the staining levels of dsRNA and HCV proteins were also comparable between HCVcc-infected ORL8c and RSc cells (IF2d7) (Fig. 7H). Colocalization of lipid droplet and HCV core protein was also observed in HCVcc-infected ORL8c and RSc cells (Supplemental Fig. 5), as previously reported (Miyanari et al., 2007). In summary, we demonstrated that ORL8c cells persistently supported the HCV life cycle.

4. Discussion

In this study, we found that human hepatoma Li23-derived cells possess the environments needed for robust genome-length HCV RNA replication and persistent production of infectious HCV. Using Li23-derived cell lines, we developed subgenomic and genome-length HCV RNA replication systems, drug assay systems, and a persistent HCV production system, which correspond to the counterparts of those using HuH-7-derived cell lines (Supplemental Table 2). It is noteworthy that the ORL8c cells cured from ORL8 cells, which were selected by the indicator of HCV RNA replication, showed good potential for producing HCV-JFH1. This finding suggests that the host factors required for robust HCV RNA replication – rather than those for HCV infection or reformation – are key determinants for reproducing the HCV life cycle in cell culture. In fact, we observed similar expression levels of the HCV entry factors between Li23- and HuH-7-derived cells. Therefore, such host factors might be commonly expressed in both ORL8c and RSc cells (Ariumi et al., 2007, 2008; Kuroki et al., 2009).

Our microarray analysis clearly demonstrated that OL8 and OL11 cell lines established in this study were not of HuH-7 cell origin, and revealed that Li23-derived cells possessed rather different expression profiles from those in HuH-7-derived cells (Fig. 3B), although similar liver-specific gene expression profiles were observed in both cell lineages (Fig. 3A). In addition, this analysis revealed that at least OL8 and OL11 cells possessed characteristic expression profiles of the parental Li23 cells, as Oc and OAc cells also showed the HuH-7-type expression profile. Therefore, further comparative studies on the mechanism(s) of HCV proliferation using Li23- and HuH-7-derived cell lines (e.g. ORL8c vs. RSc) may identify new host factor(s) required for efficient HCV proliferation.

A specific combination of adaptive mutations (Q1112R, K1609E, and S2200R) (Abe et al., 2007) is also a key determinant with which to find the Li23 cell line. Until the finding of such a combination of adaptive mutations, we had failed to establish any non-HuH-7-derived cells harboring the HCV replicon. Although it remains unclear what mechanism underlies these adaptive mutations that enhance HCV RNA replication, these mutations might be useful for the development HCV RNA replication systems of various HCV strains.

ORL8 and ORL11 assay systems might become important tools for evaluating or screening anti-HCV reagents, because these assay systems were frequently more sensitive to anti-HCV reagents than the HuH-7-derived OR6 assay system. However, the fact that the ORL8 and ORL11 assays were each more sensitive than the OR6 assay may be due to the fact that OR6 has a higher level of HCV RNA replication than ORL8 and ORL11 cells. Recently, we developed HCV replicon reporter assay systems using four genotype 1b HCV strains (1B-4, KAH5, O, and 1B-5), and found diverse sensitivities against various anti-HCV reagents among the replicons (Nishimura et al., 2009). In that study, we demonstrated that the sensitivities to anti-HCV reagents were not dependent on the replication levels of HCV RNA, and suggested that factor(s) other than the HCV RNA level are involved in conferring sensitivities to anti-HCV reagents including IFN-α (Nishimura et al., 2009). Therefore, the practical use of HuH-7- and Li23-derived assay systems would be very effective for accurately evaluating anti-HCV activity.

Finally, the most important feature of this report is that we were able to persistently produce infectious HCVcc using ORL8c cells. ORL8c-produced HCVcc would be very useful not only for verification of data obtained from HuH-7-derived cells but also for obtaining a variety of new information about the HCV life cycle.

Acknowledgments

We thank Takashi Nakamura and Atsumi Morishita for their technical assistance. We also thank S. Hirohashi, M. Namba, and D. Trono for Li21, Li24, OUMS29, IHH10.3, and IHH12 cell lines. This

work was supported by a grant-in-aid for research on hepatitis from the Ministry of Health, Labor and Welfare of Japan.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.virusres.2009.08.006.

References

Abe, K., Ikeda, M., Dansako, H., Naka, K., Kato, N., 2007. Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA. Virus Res. 125, 88–97.

Ali, S., Pellerin, C., Lamarre, D., Kukolj, G., 2004. Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line. J. Virol. 78, 491–501.

Ariumi, Y., Kuroki, M., Abe, K., Dansako, H., Ikeda, M., Wakita, T., Kato, N., 2007. DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication. J. Virol. 81, 13922–13926.

Ariumi, Y., Kuroki, M., Dansako, H., Abe, K., Ikeda, M., Wakita, T., Kato, N., 2008. The DNA damage sensors, ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication. J. Virol. 82, 9639–9646.

Bartenschlager, R., Sparacio, S., 2007. Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res. 127, 195–207.

Blight, K.J., McKeating, J.A., Rice, C.M., 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76, 13001–13014.

Burlone, M.E., Budkowska, A., 2009. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J. Gen. Virol. 90, 1055–1070.

Chevaliez, S., Pawlotsky, J.M., 2007. Interferon-based therapy of hepatitis C. Adv. Drug Deliv. Rev. 59, 1222–1241.

Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M., 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359–362.

Dansako, H., Naganuma, A., Nakamura, T., Ikeda, F., Nozaki, A., Kato, N., 2003. Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element. Virus Res. 97, 17–30.

Date, T., Kato, T., Miyamoto, M., Zhao, Z., Yasui, K., Mizokami, M., Wakita, T., 2004. Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J. Biol. Chem. 279, 22371–22376.

Gottwein, J.M., Bukh, J., 2008. Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems. Adv. Virus Res. 71, 51–133.

Hadziyannis, S.J., Sette H.Jr., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer H.Jr., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A., Ackrill, A.M., 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346–355.

Hijikata, M., Kato, N., Ootsuyama, Y., Nakagawa, M., Shimotohno, K., 1991. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl. Acad. Sci. U.S.A. 88, 5547–5551.

Hijikata, M., Mizushima, H., Tanji, Y., Komoda, Y., Hirowatari, Y., Akagi, T., Kato, N., Kimura, K., Shimotohno, K., 1993. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 90, 10773–10777.

Ikeda, M., Abe, K., Dansako, H., Nakamura, T., Naka, K., Kato, N., 2005. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem. Biophys. Res. Commun. 329, 1350–1359.

Ikeda, M., Abe, K., Yamada, M., Dansako, H., Naka, K., Kato, N., 2006. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44, 117–125.

Ikeda, M., Kato, N., 2007. Modulation of host metabolism as a target of new antivirals. Adv. Drug Deliv. Rev. 59, 1277–1289.

Ikeda, M., Sugiyama, K., Mizutani, T., Tanaka, T., Tanaka, K., Sekihara, H., Shimotohno, K., Kato, N., 1998. Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. Virus Res. 56, 157–167.

Ikeda, M., Yi, M., Li, K., Lemon, S.M., 2002. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J. Virol. 76, 2997–3006.

Kato, N., Hijikata, M., Ootsuyama, Y., Nakagawa, M., Ohkoshi, S., Sugimura, T., Shimotohno, K., 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc. Natl. Acad. Sci. U.S.A. 87, 9524–9528.

Kato, N., Nakazawa, T., Mizutani, T., Shimotohno, K., 1995. Susceptibility of human T-lymphotropic virus type 1 infected cell line MT-2 to hepatitis C virus infection. Biochem. Biophys. Res. Commun. 206, 863–869.

Kato, N., Shimotohno, K., 2000. Systems to culture hepatitis C virus. Curr. Top. Microbiol. Immunol. 242, 261–278.

Kato, N., Sugiyama, K., Namba, K., Dansako, H., Nakamura, T., Takami, M., Naka, K., Nozaki, A., Shimotohno, K., 2003a. Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro. Biochem. Biophys. Res. Commun. 306, 756–766.

Kato, T., Date, T., Miyamoto, M., Furusaka, A., Tokushige, K., Mizokami, M., Wakita, T., 2003b. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125, 1808–1817.

Kishine, H., Sugiyama, K., Hijikata, M., Kato, N., Takahashi, H., Noshi, T., Nio, Y., Hosaka, M., Miyanari, Y., Shimotohno, K., 2002. Subgenomic replicon derived from a cell line infected with the hepatitis C virus. Biochem. Biophys. Res. Commun. 293, 993–999.

Kuroki, M., Ariumi, Y., Ikeda, M., Dansako, H., Wakita, T., Kato, N., 2009. Arsenic trioxide inhibits hepatitis C virus RNA replication through modulation of the glutathione redox system and oxidative stress. J. Virol. 83, 2338–2348.

Lindenbach, B.D., Evans, M.J., Syder, A.J., Wolk, B., Tellinghuisen, T.L., Liu, C.C., Maruyama, T., Hynes, R.O., Burton, D.R., McKeating, J.A., Rice, C.M., 2005. Complete replication of hepatitis C virus in cell culture. Science 309, 623–626.

Lindenbach, B.D., Rice, C.M., 2005. Unravelling hepatitis C virus replication from genome to function. Nature 436, 933–938.

Lohmann, V., Körner, F., Koch, J., Herian, U., Theilmann, L., Bartenschlager, R., 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110–113.

Matto, M., Rice, C.M., Aroeti, B., Glenn, J.S., 2004. Hepatitis C virus core protein associates with detergent-resistant membranes distinct from classical plasma membrane rafts. J. Virol. 78, 12047–12053.

Miyanari, Y., Atsuzawa, K., Usuda, N., Watashi, K., Hishiki, T., Zayas, M., Bartenschlager, R., Wakita, T., Hijikata, M., Shimotohno, K., 2007. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. 9, 1089–1097.

Mori, K., Abe, K., Dansako, H., Ariumi, Y., Ikeda, M., Kato, N., 2008. New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C. Biochem. Biophys. Res. Commun. 371, 104–109.

Moriishi, K., Matsuura, Y., 2007. Evaluation systems for anti-HCV drugs. Adv. Drug Deliv. Rev. 59, 1213–1221.

Murakami, K., Kimura, T., Osaki, M., Ishii, K., Miyamura, T., Suzuki, T., Wakita, T., Shoji, I., 2008. Virological characterization of the hepatitis C virus JFH-1 strain in lymphocytic cell lines. J. Gen. Virol. 89, 1587–1592.

Nishimura, G., Ikeda, M., Mori, K., Nakazawa, T., Ariumi, Y., Dansako, H., Kato, N., 2009. Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to anti-HCV reagents. Antiviral Res. 82, 42–50.

Pietschmann, T., Lohmann, V., Kaul, A., Krieger, N., Rinck, G., Rutter, G., Strand, D., Bartenschlager, R., 2002. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J. Virol. 76, 4008–4021.

Saito, I., Miyamura, T., Ohbayashi, A., Harada, H., Katayama, T., Kikuchi, Y., Watanabe, Y., Koi, S., Onji, M., Ohta, Y., Choo, Q.L., Houghton, M., Kuo, G., 1990. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl. Acad. Sci. U.S.A. 87, 6547–6549.

Thomas, D.L., 2000. Hepatitis C epidemiology. Curr. Top. Microbiol. Immunol. 242, 25–41.

Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Kräusslich, H.G., Mizokami, M., Bartenschlager, R., Liang, T.J., 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791–796.

Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D.R., Wieland, S.F., Uprichard, S.L., Wakita, T., Chisari, F.V., 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U.S.A. 102, 9294–9299.

Zhu, H., Dong, H., Eksioglu, E., Hemming, A., Cao, M., Crawford, J.M., Nelson, D.R., Liu, C., 2007. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 133, 1649–1659.

Zhu, Q., Guo, J.T., Seeger, C., 2003. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J. Virol. 77, 9204–9210.

Arch Virol (2009) 154:1671–1677
DOI 10.1007/s00705-009-0502-x

ORIGINAL ARTICLE

HCV genotype 1b chimeric replicon with NS5B of JFH-1 exhibited resistance to cyclosporine A

Ken-ichi Abe · Masanori Ikeda · Yasuo Ariumi · Hiromichi Dansako · Takaji Wakita · Nobuyuki Kato

Received: 4 March 2009 / Accepted: 21 August 2009 / Published online: 25 September 2009
© Springer-Verlag 2009

Abstract Cyclosporine A (CsA) is a well-characterized anti-HCV reagent. Recently it was reported that the genotype 2a JFH-1 strain was more resistant than genotype 1 HCV strains to CsA in a cell culture system. However, the JFH-1 responsible region for the resistance to CsA remains unclear. It was also demonstrated that in genotype 1b HCVs, NS5B interacts with cyclophilin (CyP). To clarify whether or not NS5B of JFH-1 is significant for CsA resistance, we developed a chimeric replicon with NS5B of JFH-1 in the genotype 1b backbone. The chimeric replicon was more resistant to CsA than the parental genotype 1b replicon. Furthermore, reduction of CyPA had a greater effect on HCV RNA replication and sensitivity to CsA than reduction of CyPB. Here, we demonstrated that NS5B of JFH-1 contributed to this strain's CsA-resistant phenotype. NS5B and CyPA are significant for determining HCV's sensitivity to CsA.

Introduction

The combination of a pegylated interferon (IFN) with ribavirin (RBV) is the current standard therapy for chronic hepatitis C and yields a sustained virological response (SVR) rate of about 55% [6]. This means that about 45% of patients with chronic hepatitis C are still threatened by the progress of the disease to cirrhosis and hepatocellular carcinoma. To find a more effective therapy, several anti-HCV reagents have been reported using HCV replicon systems [11, 14]. Especially, cyclosporine A (CsA), which is widely used as an immunosuppressive reagent, and its derivatives, which lack immunosuppressive activity, possess anti-HCV activity [8, 18, 19]. These reagents will help to improve the SVR rate.

Cyclophilins (CyPs), CsA ligands, are a family of cellular enzymes possessing peptidyl-prolyl isomerase activity. CyP family members play significant roles in numerous cellular processes, including transcriptional regulation, immune response, protein secretion and mitochondrial function [7]. CsA possesses three major cellular targets: CyP, the calcineurin-nuclear factor of activated T-cells pathway and P-glycoprotein [7]. The mechanism of anti-HCV activity of CsA is through disassociation between CyP and HCV nonstructural protein 5B (NS5B), an RNA-dependent RNA polymerase [20]. Fernandes et al. [5] also reported that NS5A was significant in the sensitivity of HCV to CsA. However, the role of CyPs as a cellular target of CsA in HCV RNA replication remains controversial [17, 20, 21]. While genotype 1a and 1b HCV strains were highly sensitive to CsA, a genotype 2a strain, JFH-1, was less sensitive to CsA [12, 21]. Moreover, in genotype 1b HCV, interaction between CyPB and HCV NS5B is required for robust HCV RNA replication [10].

To investigate whether or not NS5B of JFH-1 is an important factor for determining sensitivity to CsA, we engineered a 1b/2a chimeric HCV subgenomic replicon derived from genotype 1b HCV-O RNA, in which NS5B and a 3′-untranslated region (UTR) were replaced with

Electronic supplementary material The online version of this article (doi:10.1007/s00705-009-0502-x) contains supplementary material, which is available to authorized users.

K. Abe · M. Ikeda (✉) · Y. Ariumi · H. Dansako · N. Kato
Department of Tumor Virology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-7558, Japan
e-mail: maikeda@md.okayama-u.ac.jp

T. Wakita
Department of Virology II, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

those of HCV JFH-1 RNA. This replicon system enables to investigate the direct effect of NS5B on the CyPs.

We report here that NS5B of JFH-1 contributes to the CsA-resistant phenotype of this strain. Furthermore, CyPA but not CyPB is essential for HCV RNA replication in 1b and 1b/2a chimeric replicon-harboring cells. Finally, supplementation with vitamin E (VE) negates the anti-HCV activity of CsA in the presence or absence of CyPs. These results contribute to our understanding of the mechanism(s) that mediate the efficacy of CsA's anti-HCV activity.

Materials and methods

Cell culture

293FT cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum. The HuH-7-derived OR6c cells were cultured as previously described [10]. The cells harboring the subgenomic replicon were maintained in the culture medium containing G418 (0.3 mg/ml; Promega, Madison, WI).

Reagents

IFN-α, IFN-γ, and VE were purchased from Sigma-Aldrich (St. Louis, MO). CsA was purchased from Calbiochem (San Diego, CA). Pitavastatin (PTV) was purchased from KOWA Co., Ltd. (Tokyo, Japan). Mizoribine (MZB) and RBV were kindly provided by Asahi Kasei Pharma (Tokyo, Japan) and Yamasa Corporation (Choshi, Japan), respectively.

Plasmid construction

The plasmid of pORN/3-5B/QR,KE,RS/5B(J) was based on pORN/3-5B/QR,KE,RS [1] and was constructed by replacing the NS5B coding region and 3′UTR with the corresponding JFH-1 sequence. The NS5A/NS5B junction was set after amino acid 2419 of HCV-O and generated by polymerase chain reaction (PCR). The sequence numbering for coding and non-coding regions was based on a sequence from GenBank: HCV-O (accession no. **AB191333**) and JFH-1 (accession no. **AB047639**). Retroviral vector pCX4bsr [2] was used as an expression vector. To obtain full-length CyPA and CyPB cDNAs, reverse transcription (RT)-PCR with KOD-plus DNA polymerase (Toyobo, Osaka, Japan) was performed as previously described [4]. The pCX4bsr/Myc-CyPA and pCX4bsr/Myc-CyPB plasmids expressing Myc-tagged CyPA and CyPB, respectively, were obtained by inserting the PCR products of full-length CyPA and CyPB into the MluI-NotI sites of the pCX4bsr/Myc vector. Expression plasmids for HA-tagged NS5B (HCV-O and JFH-1) were generated by insertion of PCR fragments encoding each HCV protein into the MluI-NotI sites of the pCX4bsr/HA vector. The sequences of all constructed plasmids were confirmed by the sequencing analysis as described previously [1].

RNA synthesis, RNA transfection, and selection of G418 cells

Plasmid DNAs were linearized by XbaI and used for the RNA synthesis with the T7 MEGAScript kit (Ambion, Austin, TX). In vitro transcribed RNA was transfected into OR6c cells by electroporation [9]. The transfected cells were selected in culture medium containing G418 (0.3 mg/ml) for 3 weeks.

RNA interference, lentiviral vector construction

A detailed description of methods of RNA interference and lentiviral vector construction is available in Supplementary Materials.

Western blot analysis

Western blot analysis was performed as described previously [1]. The antibodies used in this study were those against NS3 (Novocatra Laboratories, UK), NS5A (a generous gift from Dr. A Takamizawa, Research Foundation for Microbial Diseases, Osaka University), NS5B (1b, a generous gift from Dr. M. Kohara, Tokyo Metropolitan Institute of Medical Science), NS5B (1b/2a) [15], CyPA (BIOMOL, Plymouth Meeting, PA), CyPB (Affinity BioReagents, Rockford, IL), and β-actin (AC-15; Sigma).

Immunoprecipitation

Immunoprecipitation was performed as described previously [10]. Briefly, pre-cleared cell lysates were incubated with an anti-Myc antibody (PL14; MBL, Nagoya, Japan). Immunocomplexes were recovered by adsorption to protein G-Sepharose resin (GE Healthcare Bioscience, Uppsala, Sweden). After three washes with lysis buffer, the immunoprecipitates were analyzed by immunoblot analysis using anti-Myc and anti-HA (3F10; Roche, Mannheim, Germany) antibodies.

Evaluation of sensitivity of anti-HCV reagents

The cells were plated onto 24-well plates ($1.5–2 \times 10^4$ cells/well). After 24 h culture, the culture medium was replaced with anti-HCV reagent containing medium. After 72 h additional culture, the cells were washed with

phosphate-buffered saline once, harvested with Renilla lysis reagents (Promega), and subjected to Renilla luciferase (RL) assay according to the manufacturer's protocol.

Statistical analysis

The luciferase activities were statistically compared between the various treatment groups using Student's *t* test. *P* values of less than 0.05 were considered statistically significant.

Results

The 1b/2a chimeric replicon is less sensitive to CsA than the 1b replicon

To investigate the mechanism(s) underlying CsA's anti-HCV activity, we engineered a 1b/2a chimeric HCV subgenomic replicon derived from genotype 1b HCV-O RNA, in which the NS5B and 3′UTR regions were replaced with those of HCV JFH-1 RNA (Fig. 1a). These RNAs were transfected into OR6c cells. After 3 weeks' selection of G418, we successfully obtained a 1b replicon or 1b/2a chimeric replicon-harboring cells as polyclones (see Supplementary Material). The colony forming efficiencies of the 1b replicon and the 1b/2a chimeric replicon were 5150 ± 361 and 62 ± 10 colonies/μg RNA, respectively. Sequence analysis of HCV RNA in 1b replicon or 1b/2a chimeric replicon-harboring cells revealed that there was no conserved amino acid substitution (data not shown). The RT-quantitative PCR analysis revealed that intracellular HCV RNA copies were $3.8 \pm 0.1 \times 10^7$ and $1.1 \pm 0.1 \times 10^7$ copies/μg total RNA in 1b replicon and 1b/2a chimeric replicon-harboring cells, respectively.

Next, we examined the sensitivity of the 1b replicon and 1b/2a chimeric replicon to anti-HCV reagents (Fig. 1b). HCV RNA replication was monitored through reporter



Fig. 1 1b/2a chimeric replicon-harboring cells are less sensitive to CsA. **a** Gene organization of subgenomic RNA. RLuc and DC indicate the RL gene and the 12 N-terminal amino acid residues of the core protein as a part of internal ribosomal entry site (IRES), respectively. The positions of adaptive mutations are indicated by *asterisks*. *Shaded boxes*, *dotted open boxes*, *thin lines*, *dotted lines*, *sick lines*, and *open boxes* indicate open reading frame (ORF) derived from HCV-O strain, ORF derived from JFH-1 strain, UTR of HCV-O strain, UTR of JFH-1 strain, encephalomyocarditis virus IRES, and fusion protein RL with neomycin phosphotransferase (Neo^R), respectively. **b** Effects of various anti-HCV reagents on HCV RNA replication in the 1b replicon (*open columns*) and in the 1b/2a chimeric replicon (*closed columns*) harboring cells. The cells were treated with IFN-α, IFN-γ, CsA, PTV, RBV, and MZB, respectively. After 72 h of treatment, the RL assay was performed according to the manufacturer's protocol. The relative luciferase activity is calculated when the RL activity of untreated cells was assigned as 100% (** $P < 0.01$; *** $P < 0.001$). **c** Western blot analysis of HCV proteins. The 1b replicon or 1b/2a chimeric replicon-harboring cells were treated with CsA for 72 h. After treatment, the cell lysates were subjected to Western blot analysis. The production of NS3 and NS5A was analyzed using anti-NS3 and anti-NS5A antibodies, respectively. β-Actin was used as a control for the amount of protein loaded per lane

activity encoded by replicon RNAs in stable cell lines harboring these autonomously-replicating RNAs. The results revealed that the 1b/2a chimeric replicon was less sensitive to CsA than the 1b replicon. However, there were no differences in sensitivity to other anti-HCV reagents (IFN-α, IFN-γ, PTV, RBV, and MZB) between the 1b replicon and 1b/2a chimeric replicon (Fig. 1b). We also tested the expression levels of HCV proteins (NS3 and NS5A) in CsA-treated replicon-harboring cells (Fig. 1c). CsA decreased HCV protein expression levels in the 1b eplicon-harboring cells in a dose-dependent manner. On the other hand, in the 1b/2a chimeric replicon-harboring cells those levels were not changed at the higher concentration of CsA treatment. These results suggest that NS5B of JFH-1 decreased the sensitivity to CsA in 1b/2a chimeric replicon-harboring cells.

CyPA is essential for HCV RNA replication

It has been reported that CyPs are responsible for CsA's anti-HCV activity [17, 20, 21]. Therefore, we next examined the role of CyPs in HCV RNA replication and the anti-HCV activity of CsA using short-hairpin RNA (shRNA) against CyPA or CyPB. The silencing of CyPA or CyPB by shRNA was confirmed by Western blot analysis (Fig. 2a). The silencing of CyPA significantly suppressed HCV protein expression in 1b replicon-harboring cells and in 1b/2a chimeric replicon-harboring cells. The silencing of CyPB didn't suppress HCV protein expression in the former replicon-harboring cells and slightly suppressed in the latter replicon-harboring cells. We also demonstrated that the HCV RNA levels in these cells correlated with the results of Western blot analysis (data not shown). These results suggest that CyPA is essential for replication of both 1b and 1b/2a chimeric replicon. On the other hand, CyPB might partially affect HCV RNA replication of the 1b/2a chimeric replicon.

We next evaluated the sensitivity to anti-HCV reagents (CsA and IFN-α) between control cells and CyPs-knockdown cells. The results revealed that the sensitivity to CsA was drastically enhanced in both CyPA-knockdown 1b replicon-harboring cells and 1b/2a replicon-harboring cells (Fig. 2b), while the sensitivity to IFN-α was not dramatically changed in replicon-harboring either cells (see Supplementary Material). The silencing of CyPB slightly improved the sensitivity to CsA in the 1b/2a chimeric



Fig. 2 CyPA is essential for HCV RNA replication and modulates the anti-HCV activity of CsA. **a** Western blot analysis of HCV proteins and CyPs. The 1b replicon and 1b/2a chimeric replicon-harboring cells were transduced with the indicated shRNA for 1 week. The cell lysates were subjected to Western blot analysis. CTRL indicates the control cells transfected with the empty vector. **b** Effects of CyPs on CsA's anti-HCV activity in the 1b replicon- (*left panel*) and 1b/2a chimeric replicon- (*right panel*) harboring cells. After 72 h treatment with CsA, the RL assay was performed. The relative luciferase activity was calculated as described in Fig. 1b. The cells transfected with CTRL, CyPA, CyPB, and both CyPA and CyPB shRNA indicate *open circles*, *open triangles*, *open squares*, and *closed squares*, respectively

replicon-harboring cells but made no improvement in the 1b replicon-harboring cells. Moreover, the silencing of CyPA and CyPB additively enhanced the sensitivity to CsA in the 1b/2a chimeric replicon-harboring cells but not in the 1b replicon-harboring cells. These results suggest that the major cellular determining factor in HCV RNA replication is CyPA rather than CyPB in the 1b/2a chimeric replicon-harboring cells.

HCV NS5B interacts more strongly with CyPB than with CyPA

Although it has been reported that the interaction between CyPs and NS5B is important for HCV RNA replication using glutathione S-transferase pull-down assay [20, 21], the binding activity of NS5B to CyPs in physiological conditions remains unclear. To evaluate the interaction between CyPs and NS5B, we performed an immunoprecipitation assay using 293FT cells transfected with the expression vectors of CyPs (CyPA or CyPB) and NS5B (HCV-O or JFH-1 strain). The obtained results revealed that both NS5Bs interacted more strongly with CyPB than with CyPA. Furthermore, NS5B of HCV-O interacted more strongly with CyPs than did NS5B of JFH-1 (Fig. 3). Since CyPA expression is important for robust HCV RNA replication, these results suggest that the interaction between CyPA and NS5B might not be important for HCV RNA replication or for the anti-HCV activity of CsA.

VE completely negates CsA's anti-HCV activity in the presence or absence of CyPs

We previously reported that VE supplementation negated CsA's anti-HCV activity [22]. To rule out the possibility



Fig. 3 CyPs interact with HCV NS5B. 293FT cells were cotransfected with plasmids expressing Myc-tagged CyP and HA-tagged HCV NS5B for 48 h. The cells were lysed and subjected to immunoprecipitation with monoclonal Myc-antibody, followed by immunoblot analysis with either anti-HA (*top*) or anti-Myc (*bottom*) antibodies. CTRL indicates empty vector

that VE negates CsA's anti-HCV activity in only CyP-expressing cells, we examined whether or not VE could negate CsA's anti-HCV activity in the presence or absence of CyPs (Fig. 4). Surprisingly, VE negated CsA's anti-HCV activity in the presence or absence of CyPs. It is noteworthy that VE negated this activity more efficiently in CyPA knockdown cells than in the control or CyPB knockdown cells.

Discussion

Since it was first reported that CsA possesses anti-HCV activity, several groups have found that CsA suppresses HCV RNA replication using HCV replicon-harboring cells. In addition, the genotype 1a and 1b replicons possess high sensitivity to CsA [17, 19, 21], but the replicon of genotype 2a, JFH-1 strain, is less sensitive to CsA [12]. However, the mechanism of CsA resistance remains unclear.

Recently, Murayama et al. [16] reported that NS3 helicase and NS5B of JFH-1 were essential for robust replication using intragenotypic 2a replicon with J6 backbone. In contrast, Binder et al. [3] demonstrated that NS3 helicase from JFH-1 reduced replication efficiency of 1b/2a chimeric replicon with NS5B from JFH-1 in genotype 1b Con1 backbone. These results suggest that the effect of co-substitution of NS3 helicase with NS5B on HCV RNA replication is different between genotype 1b and 2a backbones.

In this study, we clearly demonstrated that the viral determining factor of sensitivity to CsA is NS5B, by using 1b/2a chimeric replicon-harboring cells. The homology of NS5B region between HCV-O and JFH-1 is 75% in amino acids. Fernandes et al. [5] reported amino acid change from serine to glycine at position 556 of NS5B in CsA resistant 1b replicon. Interestingly, amino acid at this position in HCV-O and JFH-1 are serine and glycine, respectively. The results indicate that the difference in amino acid sequences in NS5B between the HCV-O and JFH-1 strains contributes to the sensitivity to CsA.

Moreover, we further demonstrated that the major cellular determining factor for HCV RNA replication is CyPA rather than CyPB. CyPB is partially involved in only 1b/2a chimeric replicon RNA replication. These results suggest that decreased endogenous expression of CyPA by shRNA contributes to suppression of HCV RNA replication. Furthermore, the knockdown of CyPA enhances CsA's anti-HCV activity. Since the silencing of CyPB slightly enhanced the sensitivity to CsA in only the 1b/2a chimeric replicon-harboring cells, the expression level of CyPB might contribute to the suppression of HCV RNA replication in the case of genotype 2a, JFH-1 strain.

It has been reported that CyPB binds to NS5B and regulates its activity [20]. We also demonstrated that NS5B



Fig. 4 The effect of CsA (0.5 μg/ml) in combination with VE (10 μM) on HCV RNA replication in the 1b replicon- (*open columns*) and the 1b/2a chimeric replicon- (*closed columns*) harboring cells. After 72 h treatment, the RL assay was performed according to the manufacturer's protocol. The relative luciferase activity was calculated as described in Fig. 1b

bound to CyPB. However, our results revealed that NS5B more strongly interacted with CyPB than with CyPA. The difference in binding activity between CyPA and CyPB may be caused by subcellular localization. It has been reported that CyPA and CyPB are localized in cytoplasm and endoplasmic reticulum (ER), respectively [7]. On the other hand, NS5B localizes with ER membranes [13]. Our data, showing that NS5B interacted more strongly with CyPB than with CyPA, might be attributable to the difference in subcellular localization between cytoplasm and ER. We also demonstrated that NS5B of HCV-O interacted more strongly with CyPs than did NS5B of JFH-1. Moreover, the expression of CyPA plays a major role in robust HCV RNA replication. On the other hand, CyPB has little impact on HCV RNA replication. Taken together, these results suggest that the interaction between CyPA and NS5B might partially affect HCV RNA replication and the anti-HCV activity of CsA.

It is noteworthy that VE can negate CsA's anti-HCV activity in the presence or absence of CyPs. We also examined whether or not the combination treatment of CsA and other antioxidants (vitamin C, sodium selenate, and coenzyme Q10) could negate CsA's anti-HCV activity. Among these antioxidants, only VE negated CsA's anti-HCV activity (data not shown). Understanding VE's involvement in CsA's anti-HCV activity may help us identify factors other than the interaction between CyPA and NS5B.

CsA derivatives that affect only CyPA and that also lack immunosuppressive function will have advantages over CsA. A combination therapy of CsA or CsA derivatives with VE should be avoided so as not to affect CsA's anti-HCV activity clinically. In conclusion, we have demonstrated that NS5B of JFH-1 contributed to the CsA-resistant phenotype of this strain using 1b/2a chimeric replicon-harboring cells and CyPA is a major cellular determining factor in HCV RNA replication.

Acknowledgments We thank Dr. Trono for the VSV-G-pseudotyped HIV-1-based vector system pCMVΔR8.91, pMDG2, pSUPER, and pRDI292. We also thank A. Morishita and T. Nakamura for their technical assistance. This work was supported by a grant-in-aid for the third-term comprehensive 10-year strategy for cancer control and by a grant-in-aid for research on hepatitis, both from the Ministry of Health, Labor and Welfare of Japan. K. A. was supported by a Research Fellowship from the Japan Society for the Promotion of Science for Young Scientists.

References

1. Abe K, Ikeda M, Dansako H, Naka K, Kato N (2007) Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA. Virus Res 125:88–97
2. Akagi T, Sasai K, Hanafusa H (2003) Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation. Proc Natl Acad Sci USA 100:13567–13572
3. Binder M, Quinkert D, Bochkarova O, Klein R, Kezmic N, Bartenschlager R, Lohmann V (2007) Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. J Virol 81:5270–5283
4. Dansako H, Naganuma A, Nakamura T, Ikeda F, Nozaki A, Kato N (2003) Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element. Virus Res 97:17–30
5. Fernandes F, Poole DS, Hoover S, Middleton R, Andrei AC, Gerstner J, Striker R (2007) Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology 46:1026–1033
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982

7. Fruman DA, Burakoff SJ, Bierer BE (1994) Immunophilins in protein folding and immunosuppression. Faseb J 8:391–400
8. Goto K, Watashi K, Murata T, Hishiki T, Hijikata M, Shimotohno K (2006) Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem Biophys Res Commun 343:879–884
9. Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, Kato N (2005) Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun 329:1350–1359
10. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N (2006) Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44:117–125
11. Ikeda M, Kato N (2007) Modulation of host metabolism as a target of new antivirals. Adv Drug Deliv Rev 59:1277–1289
12. Ishii N, Watashi K, Hishiki T, Goto K, Inoue D, Hijikata M, Wakita T, Kato N, Shimotohno K (2006) Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 80:4510–4520
13. Miyanari Y, Hijikata M, Yamaji M, Hosaka M, Takahashi H, Shimotohno K (2003) Hepatitis C virus non-structural proteins in the probable membranous compartment function in viral genome replication. J Biol Chem 278:50301–50308
14. Moriishi K, Matsuura Y (2007) Evaluation systems for anti-HCV drugs. Adv Drug Deliv Rev 59:1213–1221
15. Murakami K, Kimura T, Osaki M, Ishii K, Miyamura T, Suzuki T, Wakita T, Shoji I (2008) Virological characterization of the hepatitis C virus JFH-1 strain in lymphocytic cell lines. J Gen Virol 89:1587–1592
16. Murayama A, Date T, Morikawa K, Akazawa D, Miyamoto M, Kaga M, Ishii K, Suzuki T, Kato T, Mizokami M, Wakita T (2007) The NS3 helicase and NS5B-to-3'X regions are important for efficient hepatitis C virus strain JFH-1 replication in Huh7 cells. J Virol 81:8030–8040
17. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, Chen CH, Kakinuma S, Oooka S, Maekawa S, Enomoto N, Watanabe M (2005) Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 129:1031–1041
18. Paeshuyse J, Kaul A, De Clercq E, Rosenwirth B, Dumont JM, Scalfaro P, Bartenschlager R, Neyts J (2006) The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43:761–770
19. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K (2003) Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282–1288
20. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, Shimotohno K (2005) Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 19:111–122
21. Yang F, Robotham JM, Nelson HB, Irsigler A, Kenworthy R, Tang H (2008) Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol 82:5269–5278
22. Yano M, Ikeda M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, Kato N (2007) Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrob Agents Chemother 51:2016–2027

J Gastroenterol (2009) 44:856–863
DOI 10.1007/s00535-009-0075-1

ORIGINAL ARTICLE—LIVER, PANCREAS, AND BILIARY TRACT

Interferon-α-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway

Azusa Matsumoto · Tatsuki Ichikawa · Kazuhiko Nakao · Hisamitsu Miyaaki · Kumi Hirano · Masumi Fujimito · Motohisa Akiyama · Satoshi Miuma · Eisuke Ozawa · Hidetaka Shibata · Shigeyuki Takeshita · Hironori Yamasaki · Masanori Ikeda · Nobuyuki Kato · Katsumi Eguchi

Received: 28 July 2008 / Accepted: 14 April 2009 / Published online: 13 May 2009
© Springer 2009

Abstract
Object The interferon-induced Jak-STAT signal alone is not sufficient to explain all the biological effects of IFN. The PI3-K pathways have emerged as a critical additional component of IFN-induced signaling. This study attempted to clarify that relationship between IFN-induced PI3-K-Akt-mTOR activity and anti-viral action.
Result When the human normal hepatocyte derived cell line was treated with rapamycin (rapa) before accretion of IFN-α, tyrosine phosphorylation of STAT-1 was diminished. Pretreatment of rapa had an inhibitory effect on the IFN-α-induced expression of PKR and p48 in a dose dependent manner. Rapa inhibited the IFN-α inducible IFN-stimulated regulatory element luciferase activity in a dose-dependent manner. However, wortmannin, LY294002 and Akt inhibitor did not influence IFN-α inducible luciferase activity. To examine the effect of PI3-K-Akt-mTOR on the anti-HCV action of IFN-α, the full-length HCV replication system, OR6 cells were used. The pretreatment of rapa attenuated its anti-HCV replication effect in comparison to IFN-α alone, whereas the pretreatment with PI3-K inhibitors, wortmannin and LY294002 and Akt inhibitor did not influence IFN-induced anti-HCV replication.
Conclusion IFN-induced mTOR activity, independent of PI3K and Akt, is the critical factor for its anti-HCV activity. Jak independent mTOR activity involved STAT-1 phosphorylation and nuclear location, and then PKR is expressed in hepatocytes.

Keywords mTOR · STAT-1 · Interferon · HCV · PKR

Abbreviations

IFN	Interferon
HCV	Hepatitis C virus
STAT	Signal transducers and activators of transcription
ISGF-3	IFN-stimulated gene factor 3
ISRE	IFN-stimulated regulatory element
PKR	Double-stranded RNA-dependent protein kinase
Rapa	Rapamycin
PI3-K	Phosphatidylinositol 3-kinase
mTOR	Mammalian target of rapamycin
siRNA	Small interfering RNA

Introduction

Currently, a chronic hepatitis C virus (HCV) infection is the major cause of hepatocellular carcinoma worldwide [1]. Therefore, an anti-HCV strategy is important for prevention of carcinogenesis. Advancement in the treatment of HCV by a combination of pegylated interferon (IFN) and

A. Matsumoto · K. Hirano
Department of Clinical Pharmaceutics,
Graduate School of Biomedical Sciences,
Nagasaki University, Nagasaki, Japan

T. Ichikawa (✉) · K. Nakao · H. Miyaaki · M. Fujimito · M. Akiyama · S. Miuma · E. Ozawa · H. Shibata · S. Takeshita · K. Eguchi
The First Department of Internal Medicine,
Graduate School of Biomedical Sciences, Nagasaki University,
1-7-1 Sakamoto, Nagasaki 852-8501, Japan
e-mail: ichikawa@net.nagasaki-u.ac.jp

H. Yamasaki
Health Research Center, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan

M. Ikeda · N. Kato
Department of Molecular Biology, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan

ribavirin is effective in 80% of HCV genotype 2 or 3 cases, but less than 50% of genotype 1 cases. To ameliorate the salvage rate of HCV infection, new anti-HCV agents have been developed to inhibit the life cycle of HCV and are combined with IFN-α [2]. Since IFN-α is the most basic agent for HCV treatment, it is necessary to improvement the salvage rate of HCV infection by clarifying the efficacy of IFN treatment.

The factors associated with a refractory response to IFN treatment are the HCV genotype, viral load, age, sex, fibrosis of the infected liver and metabolic factors such as insulin resistance and steatosis [3]. Increased hepatic expression of the suppressor of cytokine signaling (SOCS) family, known as the Jak-STAT signal inhibitors, especially SOCS-3, is associated with non-response to IFN treatment [4, 5]. It is thought that inflammatory cytokines, such as, interleukin 6, induced by HCV infection can induce SOCS-3 in hepatocyte [5]. SOCS-3 inhibits IFN-induced tyrosine phosphorylation of Jak, then intra-hepatocyte IFN signal transduction is inhibited. For HCV survival, Jak1, Tyk2 and STAT-1,-2 signaling, which is the essential pathway for type 1 IFN-induced anti-viral activity, becomes the attack targets from HCV. The relative lack of a viral response to IFN treatment is associated with blunted IFN signaling [6]. HCV coding proteins also inhibit STAT-1 tyrosine phosphorylation [7]. The cause of a refractory response to IFN treatment is thought to be HCV-induced Jak-STAT signal inhibition.

Type 1 IFN is a pleiotropic cytokine which activates various intra-cellular signal pathways other than the Jak-STAT signal [8]. Additional signaling pathways could either collaborate with STATs at the promoter level and contribute to the activation of the STATs plus transcription factor genes or function totally independent of any STAT factors, thus leading to the activation of transcription factor only genes [8]. The Jak-STAT signal alone is not sufficient to explain all the biological effects of type 1 IFN. The PI3-K and p38 kinase pathways have emerged as critical additional component of IFN-induced signaling [8–10]. p38, activated via IL-1β is enhanced STAT-1 tyrosine phosphorylation and express the anti-viral protein, PKR [9]. The IFN-induced PI3-K-Akt pathway has Jak independent activation, and it is the critical signal for cell survival and insulin action [10], but its relationship with the anti-viral action and PI3-K-Akt pathway is still unclear.

Recently, mTOR, a downstream kinase of PI3-K-Akt pathway, was shown to play a critical role in protein synthesis and anti-viral effects. Kaur and his colleagues [11] reported that the IFN activated mTOR pathway exhibits important regulatory effects in the generation of the IFN responses, including the anti-encephalo myocarditis virus effect. The IFN-induced mTOR is LY294002 sensitive and does not affect the IFN-stimulated regulatory element (ISRE) dependent promoter gene activity. Human cytomegalovirus is inhibited by 5′-AMP-activted protein kinase mediated inhibition of mTOR kinase [12]. In contrast, vesicular stomatitis virus is mTOR dependent [13]. A relationship has been reported between the replication of hepatitis virus and mTOR activity. p21-activated kinase 1 is activated through the mTOR/p70 S6 kinase pathway and regulates the replication of HCV [14]. mTOR activation is dependent upon the PI3-K-Akt and ERK pathways. Gao and colleagues reported that HCV-NS5A protein activates the PI3-K-Akt-mTOR pathway and could inhibit HBV RNA transcription and reduce HBV DNA replication in HepG2 cells [15]. The activation of the N-Ras-PI3-K-Akt-mTOR pathway by HCV is required for cell survival and HCV replication [16]. Therefore, PI3-K, Akt and mTOR activated by HCV are inhibitory signals of HCV replication and survival signals of HCV infected cells. Furthermore, the PI3-K-Akt-mTOR pathway, which is activated by HCV, is thought to be one mechanism for chronic HCV infection [14–16]. However, type 1 IFN-induced PI3-K, Akt and mTOR have not yet been fully evaluated regarding their influence on HCV replication.

This study investigated whether IFN-α induced the PI3-K-Akt-mTOR pathway, whether the Jak-STAT pathway has a relationship with the PI3-K-Akt-mTOR pathway, and, finally, whether IFN induced signal transduction, other than the Jak-STAT pathway, is associated with the anti-HCV activity.

Materials and methods

Reagents and cell culture

Recombinant human IFN-α2b was a generous gift from Schering-Plough KK (Tokyo, Japan). Wortmannin, LY 294002, Akt inhibitor and rapamycin were purchased from Calbiochem (La Jolla, CA, USA). Hc human hepatocyte cells (Applied Cell Biology Research Institute, Kirkland, WA, USA) and HuH-7 human hepatoma cells (American Type Culture Collection, Rockville, MD, USA) were maintained in a chemically defined medium, CS-C completed (Cell Systems, Kirkland, WA, USA) and RPMI (Invitrogen, Grand Island, NY, USA), respectively, supplemented with 5% fetal bovine serum. In the pretreatment of rapamycin and chemical inhibitors for 3 h, the cells were

cultured in 5% RPMI, and then exchanged the medium and treated the cells with IFN-α2b at the indicated time.

Cell viability assay

The cells were measured using the colorimetric cell viability assay method. Cell viability was determined by the colorimetric method using a Cell Counting kit (Wako Life Science, Osaka, Japan). The absorbance of each well was measured at 405 nm with a microtiter plate reader (Multiskan JX, Thermo BioAnalysis Co., Japan). After 2 days of 100 IU/mL IFN-α and 1000 nmol/L rapamycin treatment, Cell viability is expressed as a percentage of the viability in standard media without IFN-α and rapamycin. Data were expressed as the mean ± standard deviation (SD). Statistical significance was assessed using Student's *t* test. Statistical difference was defined as $P < 0.05$. All numerical results were reported as the mean of four independent experiments.

Western blotting and antibodies

Western blotting with anti-PKR, anti-STAT-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-tyrosine-701 phosphorylated STAT-1, anti-serine-727 phosphorylated STAT-1, anti-p48, anti-serine-437 phosphorylated Akt, anti-threonin-308 phosphorylated anti-Akt, anti-Akt, anti-serine-2448 phosphorylated mTOR, anti-serine-2481 phosphorylated mTOR, anti-mTOR, anti-JAK-1 or anti-tyrosine 1022/1023 JAK-1 (Cell Signaling, Beverly, MA, USA) was performed as described previously [9]. Briefly, Hc cells were lysed by the addition of a lysis buffer (50 mmol/L Tris–HCl, pH 7.4, 1% Np40, 0.25% sodium deoxycholate, 0.02% sodium azide, 0.1% SDS, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L PMSF, 1 μg/mL each of aprotinin, leupeptin and pepstatin, 1 mmol/L sodium o-vanadate and 1 mmol/L NaF). The samples were separated by electrophoresis on 8–12% SDS polyacrylamide gels and electrotransferred to nitrocellulose membranes, and then blotted with each antibody. The membranes were incubated with horseradish peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG, and the immunoreactive bands were visualized using the ECL chemiluminescence system (Amersham Life Science, Buckinghamshire, England).

Fluorescence immunohistochemistry

The Hc cells were seeded onto 11-mm glass cover-slips in 24-well plates at 2.4×10^5 cells/well. The next day, the medium was replaced with serum-free medium, and the cells were pretreated with 10 or 100 nmol/L rapamycin, or vehicle, for 3 h and then stimulated with 100 IU/mL IFN-α for 10 min. Fluorescence immunohistochemistry was performed as described previously [17]. The cells were incubated with anti-tyrosine-701 phosphorylated STAT1 antibody for 1 h at room temperature, washed three times in PBS, incubated with rhodamine-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) for 1 h, washed in PBS, and mounted in Vectashield Mounting Medium (Vector Laboratories Inc., Burlingame, CA, USA). Nuclear staining was performed using Hoechst 33258 (Invitrogen Japan K.K., Tokyo, Japan). An immunofluorescence analysis was done using an Olympus BX50 microscope (Tokyo, Japan) and the image was captured by a Nikon DXM 1200 digital camera (Tokyo, Japan).

Reporter gene assay

A pISRE-Luc cis-reporter plasmid containing five copies of the ISRE sequence and the firefly luciferase gene and pRL-SV40 containing the SV40 early enhancer/promoter and the renilla luciferase gene were obtained from Clontech (San Diego, CA, USA) and Promega (Madison, WI, USA), respectively. The HuH-7 cells were grown in 24-well multiplates and transfected with 1 μg of pISRE-Luc and 10 ng of pRL-SV40 as a standard by the lipofection method. One day later, the cells were incubated in the absence or presence of varying concentrations of chemical blockers and IFN-α, and the luciferase activities in the cells were determined using a dual-luciferase reporter assay system and a TD-20/20 luminometer (Promega). The data were expressed as the relative ISRE-luciferase activity.

HCV replicon system

OR6 cells stably harboring the full-length genotype 1 replicon, ORN/C-5B/KE [18], were used to examine the influence of the anti-HCV effect of IFN. The cells were cultured in Dulbecco's modified Eagle's medium (Gibco-BRL, Invitrogen) supplemented with 10% fatal bovine serum, penicillin and streptomycin and maintained in the presence of G418 (300 mg/L; Geneticin, Invitrogen). This replicon was derived from the 1B-2 strain (strain HCV-o, genotype 1b), in which the *Renilla* luciferase gene is introduced as a fusion protein with neomycin to facilitate the monitoring of HCV replication. After the treatment, the cells were harvested with *Renilla* lysis reagent (Promega, Madison, WI, USA) and then were subjected to a luciferase assay according to the manufacturer's protocol. mTOR gene knock down is used siRNA (Cell Signaling). 100 nmol/L mTOR specific and non-targeted siRNA as a control was transfected to OR6 cells in accordance with the appended manual. One day later, the cells were incubated in either the absence or presence of 10 IU/mL IFN-α.

Results

IFN-α-induced activity of STAT-1 is inhibited by rapamycin pretreatment

To attempt to clearly identify the influence of mTOR to IFN-α-induced anti-viral protein expression rapamycin (rapa), the specific inhibitor of mTOR, was added prior to treatment with IFN-α. Hc cells have been used as normal hepatocytes in previous reports [19]. The Hc cells were incubated in the absence or presence of IFN-α with or without pretreatment with rapa for 2 h the cells were then harvested for the Western blot analysis (Fig. 1). IFN-α clearly induced tyrosine and serine phosphorylation of STAT-1 at 5 (Fig. 1a, lane 4) and 10 min (Fig. 1a, lane 6), respectively, in the absence of rapa. However, when the Hc cells were pretreated with rapa before IFN-α stimulation, the levels of tyrosine and serine phosphorylated STAT-1 were clearly and rapidly lower than those induced by IFN-α alone 5 min after treatment in tyrosine (Fig. 1a, lane 5). Jak-1, an upstream protein of STAT-1, was equally phosphorylated by IFN-α with (Fig. 1b, lane3) or without (Fig. 1b, lane2) pretreatment with rapa. The viability of the Hc cells was 1 in vehicle, 0.93±0.21 in IFN-α treatment and 0.88±0.34 in rapamycin treatment. No difference in the cell viability the among vehicle, IFN-α and rapamycin treatment was not recognized in our assay. The viability of the HuH-7 and OR6 cells also demonstrated no difference between the presence of IFN-α and rapamycin treatment and the absence thereof.

IFN inducible gene products are diminished by pretreatment of rapamycin

Since pretreatment with rapa inhibited the IFN-α induced STAT-1 activity, the phosphorylation of tyrosine and serine and nuclear translocation, the effect of pretreated with rapa on the IFN-α inducible gene product was examined. The protein levels of PKR, an anti-viral protein that acts as a mRNA translation inhibiter activated by double stranded RNA [20, 21], and p48, key component of ISGF-3 with activated STAT-1 and -2 [22], were induced by IFN-α treatment for 3 h in Hc cells (Fig. 1c, lanes 1, 2). However, pretreatment with rapa had an inhibitory effect on IFN-α-induced PKR and p48 in a dose dependent manner (Fig. 1c, lanes 2–4).

The serine 473 on Akt and serine 2448 on mTOR are phosphorylated by IFN-α

Because pretreatment with rapa affected the IFN-α signaling (Fig. 1), the ability of IFN-α to activate the Akt-mTOR pathway was investigated. The phosphorylation of serine-2448 residues of mTOR and serine-473 residue of



Fig. 1 Alteration in the distribution of IFN-α induced phosphorylated STAT-1 (**a**) and Jak-1 (**b**) by rapamycin and effect of rapamycin on IFN-α-induced PKR and p48 (**c**). Hc cells were pretreated without (*lanes 1, 2, 4, 6,* and *8*) or with 1 μmol/L rapa (*lanes 3, 5, 7,* and *9*). These Hc cells were stimulated by 100 IU/L IFN-α (*lane 2–9*) for 30 min. Phosphorylated STAT-1 at tyrosine-701 residue (*upper panel*) and at serine-727 residue (*lower panel*) were analyzed by Western blotting. **a** After pretreatment of 1000 nmol/L rapa (*lane 3*) for 3 h, Hc cells were untreated (*lane 1*) or treated with 100 IU/mL IFN-α (*lanes 2, 3*) for 3 min, then phosphorylated JAK-1 at tyrosine-1022/1023 residue (*first panel*), expression of JAK-1 (*second panel*) were analyzed by Western blotting (**b**). Hc cells were treated with 100 IU/mL of IFN-α in the absence (*lane 2*) or of the presence of pretreatment (*lane 3, 4*). *Lane 1* was not treated IFN-α and calcineurin inhibitors. One day latter, PKR and p48 was determined by Western blotting (**c**)



Fig. 2 Effect of IFN-α on Akt and mTOR (**a**) and effect of Akt inhibitor (**b**) and LY294002 (**c**) on IFN-α-induced tyrosine phosphorylated STAT-1 and Serine phosphorylated mTOR (**d**). Hc cells were stimulated by 100 IU/L IFN-α for 60 min. At the indicated time, the cells were harvested. Phosphorylated Akt at serine-473 residue (*first panel*), Akt (*second panel*), mTOR at serine-2448 residue (*third panel*) and mTOR (*fourth panel*) were analyzed by Western blotting. After pretreatment with 5 or 20 μmol/L Akt inhibitor (*lane 3*, and 4, respectively) (**b**) and 1 or 10 nmol/L LY294002 (*lane 3* and *4*, respectively) (**c**) for 3 h, Hc cells were untreated (*lane 1*) or treated with 100 IU/mL IFN-α (*lanes 2–4*) for 5 min and phosphorylated STAT-1 at tyrosine-701 residue (*first panel*), expression of STAT-1 (*second panel*) were analyzed by Western blotting. **d** After pretreatment with 100 nmol/L wortmannin (*lane 2*) and 1 nmol/L LY294002 (*lane 3*) for 3 h, the Hc cells were either untreated (*lane 1*) or treated with 100 IU/mL IFN-α (*lanes 2–4*) for 10 min and then were phosphorylated mTOR at Serine-2448 residue (*first panel*), the expression of mTOR (*second panel*) was analyzed by Western blotting

Akt by 100 IU/ml of IFN-α was detected at 5 min and at 60 min after IFN-α treatment, respectively (Fig. 2a). The band intensity of serine 2448 phosphorylated mTOR increased at 30 min and decreased at 60 min after IFN-α treatment. In contrast, a slight band intensity of serine phosphorylated 473 Akt was only detected at 60 min after IFN-α treatment. In addition, a Western blot analysis of phosphorylated serine 2481 of mTOR and threonine 308 Akt was conducted under the same conditions as Fig. 2a, but no bands were detected (data not shown). In Fig. 2d, IFN-α-induced Serine 2448 phosphorylated mTOR was not inhibited by PI3-K inhibitors (lanes 2, 3).

The IFN-α-induced nuclear translocation of tyrosine phosphorylated STAT-1 was inhibited by pretreatment with rapa

The location of tyrosine phosphorylated STAT-1 was evaluated by fluorescence immunohistochemistry of cultured Hc cells (Fig. 3). The IFN-α-induced nuclear translocation of tyrosine phosphorylated STAT-1 was observed (Fig. 3c), but its translocation was inhibited by pretreatment with rapa and the inhibition of the translocation of STAT-1 was more definitive at 1000 nmol/L rapa (Fig. 3e) than 100 nmol/L (Fig. 3g).

IFN-α-induced ISRE-contained promoter activity is inhibited by pretreatment of rapa, but not by wortmannin, LY294002 and Akt inhibitor

The influence of pretreatment of PI3-K-Akt-mTOR inhibitors on IFN-α inducible luciferase activity of the ISRE-containing promoter was examined. Since Hc cells were not sufficient for reporter gene transfection, HuH-7 cells were used in the transfection assay. HuH-7 cells were transfected with pISRE-Luc containing five repeats of the ISRE sequence and pRV-SV40 as a standard and then were treated with IFN-α after 3 h with or without pretreatment with rapa, wortmannin, LY294002 or Akt inhibitor. Rapa inhibited IFN-α inducible luciferase activity in a dose-dependent manner (Fig. 4, lane 2–4). However, wortmannin and LY294002, PI3-K inhibitor, and Akt inhibitor had no effect on IFN-α inducible luciferase activity (Fig. 4, lanes 2, 5–7).

The expression of IFN-α-induced tyrosine phosphorylated STAT-1 was determined after pretreatment with Akt inhibitor and LY294002 to evaluate the result of luciferase assay (Fig. 4). The Hc cells were incubated under the same conditions used in Fig. 4, but phosphorylated STAT-1 was not inhibited by the Akt inhibitor (Fig. 2b) and LY294002 (Fig. 2c).



Fig. 3 Inhibition of IFN-α-induced nuclear translocation of phosphorylated STAT-1 by rapamycin. The Hc cells were pretreated without (**a–d**) or with 1000 nmol/L rapa (**e**, **f**) or 100 nmol/L rapa (**g**, **h**). After pretreatment, the Hc cells were stimulated by 100 IU/L IFN-α (**c–h**) for 30 min. Thereafter, the cells were fixed, permeabilized, processed for immunofluorescence (**a**, **c**, **e**, **g**) and Hoechst staining (**b**, **d**, **f**, **h**), and visualized by fluorescence microscopy. The results shown are from one representative experiment from a total of three performed



Fig. 4 Suppression effect of rapamycin, not PI3-k inhibitors and Akt inhibitor, on IFN-α-induced reporter gene assay. HuH-7 cells transfected with reporter gene (pISRE-Luc and pRL-SV40) were either untreated (*lane 1*) or pretreated with rapa (*lane 3*, *4*), wortmannin (*lane 5*), LY294002 (*lane 6*) or Akt inhibitor (*lane 7*) for 3 h, followed by IFN-α 100 IU/mL (*lanes 2–7*). Six hour later, the relative ISRE-luciferase activity ($n = 4$) was determined as described in the "Materials and methods". The data are expressed as the mean ± SD and are representative example of four similar experiments



Fig. 5 Alternation of IFN-α suppressed HCV replication by rapamycin, but not PI3-K inhibitors and Akt inhibitor. OR6 cells, a full-length replicon system, were treated with 100 IU/mL of IFN-α in the absence (*lane 2*) or presence of pretreatment (*lanes 3–8*) for 3 h. *Lane 1* was not treated IFN-α alone. One day latter, *Renilla* luciferase activity was determined by luminometer ($n = 4$). The data are expressed as the mean ± SD and are representative example of four similar experiments

Rapamycin and mTOR specific siRNA, but not PI3-K inhibitor and Akt inhibitor can cancel the IFN-α-induced anti-HCV replicon activity

OR6 cells the full-length HCV replication system was used to examine the anti-viral effect of PI3-K, Akt and mTOR on IFN-α stimulation. The cells were treated with IFN-α after 3 h in the presence or absence of rapa, Akt inhibitor or PI3-K inhibitor (Fig. 5). Pretreatment with rapa attenuated its anti-HCV replication effect in comparison to IFN-α alone (Fig. 5, lanes 1–4), whereas pretreatment with PI3-K inhibitors and Akt inhibitor did not increase the *Renilla* luciferase activity (Fig. 5, lanes 1, 2, 5–8). We performed siRNA transfection for mTOR knock down (Fig. 6). Although transfection efficiency of siRNA is barely 10%, IFN-α-induced anti-HCV action was clearly inhibited in siRNA against mTOR transfected cells (lane 5) in comparison to the control cells (lane 6).

Discussion

Rapa inhibited the IFN-α-induced tyrosine and serine phosphorylation and nuclear translocation of STAT-1, the ISRE-promoter activity, the expression of PKR and the replication of HCV replicon. This suggests that the IFN-induced mTOR activity, through Jak independent STAT-1 phosphorylation, is a critical signal for IFN-induced anti-HCV action. Interestingly, mTOR activated by IFN was PI3-K-Akt independent in this study.



Fig. 6 Alternation of IFN-α suppressed HCV replication by siRNA against mTOR. The OR6 cells were transfected the siRNA against mTOR (*lanes 2, 5*) and the non-targeted siRNA (*lanes 3, 6*). One day later, the cells were IFN-α treatment (*lanes 4–6*). HCV replicon assay is same as Fig. 5. The data are expressed as the mean ± SD and are representative example of four similar experiments

mTOR activity may have an inhibitory action on HCV replication through STAT-1 phosphorylation, but not the translation initiation action of mTOR. This study assumed that IFN-induced PKR expression and ISRE-luciferase activity were inhibited by rapa as the result of a suppression effect on IFN inducible STAT-1 activation. IFN inducible PKR contributes the anti-HCV action [20], and anti-HCV action of ribavirin is also attributable to its ability to up-regulate PKR activity [21]. Previous reports revealed that the mTOR activity did not influence the HCV-IRES activity because the viral promoter has cap-independent translation [23]. Although mTOR is the mRNA translational regulator through phosphorylation of a downstream target such as 4E-BP and S6K [24], we think that the IFN-induced mTOR activity influences the phosphorylation of STAT-1 in our study (Fig. 1). In addition, it is thought that the alternation of STAT-1 phosphorylation by the mTOR activity influences the gene expression of anti-virus protein and IFN-induced anti-viral action.

In our study, serine-473 on Akt showed a delayed phosphorylation in comparison to that of serine-2448 on mTOR after IFN stimulation (Fig. 2a). Since serine-473 on Akt is phosphorylated by mTOR/Rictor/GβL [25, 26] and a PDK-1 independent pathway [25], IFN-induced serine-473 phosphorylated Akt may not involve the mTOR activity. Therefore, PI3-K inhibitor and Akt inhibitor had no effect on IFN inducible anti-HCV action. The pathway of mTOR activation is prismatic. PI-3Ks, upstream kinase of Akt and mTOR, are grouped into three classes (I–III), according to their substrate preference and sequence homology [27]. PI3-k inhibitor, wortmannin and LY294002, inhibit class I and III PI3-Ks, and to a lesser extent class II PI3-K, upstream kinase of Akt [27]. In our study, neither PI3-K nor Akt inhibitor inhibited IFN-induced ISRE luciferase activity and loss of HCV replication (Figs. 4, 5). These results indicate that the IFN-induced anti-HCV activity is mTOR dependent, but not PI3-K and Akt dependent. In the current report, the production of IL-1 receptor antagonist in IFN-stimulated monocytes depends on the PI3-K pathway, but not STAT-1 [28], and chronic myelogenous leukemia cells are differentially regulated by the IFN-induced PI3-K-Akt-mTOR pathway with no relation to STAT-1 phosphorylation [29]. Similar to the findings of those reports, the PI3-K-Akt pathway has been reported to be generally independent of the STAT activity [10]. Therefore, the difference in the cell type [8] may explain the discrepancy between these data and our data. We therefore speculate that in hepatocytes, unlike lymphoid cells, IFN-induced mTOR activity is not dependent on the PI3-K activity. In addition, the mTOR activity is not related to the STAT activity in lymphoid cells. However, in hepatocytes, the IFN-induced mTOR activity was closely linked to the IFN-induced STAT activity in our study.

mTOR is a serine and threonine kinase [10]. Phosphorylation of STATs by mTOR occurs also on a serine residue, but not tyrosine [10, 30]. The mTOR pathway is critical for IFN-γ-induced suppression of tyrosine phosphorylated STAT-3 in a prostate cancer cell line [31]. Although this is not consistent with the results of our study, this also showed mTOR to be associated with tyrosine phosphorylation without reference to SOCS and phosphatase. In addition, in a mouse embryo fibroblast cell line, IFN-γ-induced tyrosine and serine phosphorylation of STAT-1 is inhibited by rapa [32], while in the hepatoma cell line, HLF, IFN-β stimulated STAT-1 tyrosine phosphorylation partially decreases by LY294002, but the effect of rapa has not yet been studied [33]. In the current study [31–33], not only STAT-1 serine phosphorylation but also tyrosine was found to be downstream of the IFN induced mTOR activity; however, the mechanism controlling the tyrosine phosphorylation of STAT-1 and the mTOR activity, remains to be elucidated.

In conclusion, IFN-induced mTOR activity, independent of PI3-K and Akt, is the critical factor for anti-HCV action. The Jak independent mTOR activity is, therefore, involved in STAT-1 phosphorylation and nuclear location, thus resulting in the development of IFN-induced anti-HCV protein, especially the expression of PKR, in HCV-infected hepatocytes.

References

1. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50.
2. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology. 2007;132:1979–98.
3. Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology. 2007;46:1009–15.
4. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. 2006;55:529–35.
5. Huang Y, Feld JJ, Sapp RK, Nanda S, Lin JH, Blatt LM, et al. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology. 2007;132:733–44.
6. Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol. 2007;81:3391–401.
7. Lan KH, Lan KL, Lee WP, Sheu ML, Chen MY, Lee YL, et al. HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines. J Hepatol. 2007;46:759–67.
8. van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity. 2006;25:361–72.
9. Ichikawa T, Nakao K, Nakata K, Yamashita M, Hamasaki K, Shigeno M, et al. Involvement of IL-1beta and IL-10 in IFN-alpha-mediated antiviral gene induction in human hepatoma cells. Biochem Biophys Res Commun. 2002;294:414–22.
10. Kaur S, Uddin S, Platanias LC. The PI3' kinase pathway in interferon signaling. J Interferon Cytokine Res. 2005;25:780–7.
11. Kaur S, Lal L, Sassano A, Majchrzak-Kita B, Srikanth M, Baker DP, et al. Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem. 2007;282:1757–68.
12. Kudchodkar SB, Del Prete GQ, Maguire TG, Alwine JC. AMPK-mediated inhibition of mTOR kinase is circumvented during immediate-early times of human cytomegalovirus infection. J Virol. 2007;81:3649–51.
13. Minami K, Tambe Y, Watanabe R, Isono T, Haneda M, Isobe K, et al. Suppression of viral replication by stress-inducible GADD34 protein via the mammalian serine/threonine protein kinase mTOR pathway. J Virol. 2007;81:11106–15.
14. Ishida H, Li K, Yi M, Lemon SM. p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells. J Biol Chem. 2007;282:11836–48.
15. Guo H, Zhou T, Jiang D, Cuconati A, Xiao GH, Block TM, et al. Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-Akt signal transduction pathway. J Virol. 2007;81:10072–80.
16. Mannova P, Beretta L. Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication. J Virol. 2005;79:8742–9.
17. Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M, et al. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. Int J Oncol. 2006;29:713–9.
18. Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, Kato N. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun. 2005;329:1350–9.
19. Obora A, Shiratori Y, Okuno M, Adachi S, Takano Y, Matsushima-Nishiwaki R, et al. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology. 2002;36:1115–24.
20. Wang C, Pflugheber J, Sumpter R Jr, Sodora DL, Hui D, Sen GC, et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol. 2003;77:3898–912.
21. Liu WL, Su WC, Cheng CW, Hwang LH, Wang CC, Chen HL, et al. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus. J Infect Dis. 2007;196:425–34.
22. Tamada Y, Nakao K, Nagayama Y, Nakata K, Ichikawa T, Kawamata Y, et al. p48 Overexpression enhances interferon-mediated expression and activity of double-stranded RNA-dependent protein kinase in human hepatoma cells. J Hepatol. 2002;37:493–9.
23. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67:10804–12.
24. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene. 2006;25:6416–22.
25. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT–a major therapeutic target. Biochim Biophys Acta. 2004;1697:3–16.
26. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3–L1 adipocytes. J Biol Chem. 2005;280:40406–16.
27. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–19.
28. Molnarfi N, Hyka-Nouspikel N, Gruaz L, Dayer JM, Burger D. The production of IL-1 receptor antagonist in IFN-beta-stimulated human monocytes depends on the activation of phosphatidylinositol 3-kinase but not of STAT1. J Immunol. 2005;174:2974–80.
29. Parmar S, Smith J, Sassano A, Uddin S, Katsoulidis E, Majchrzak B, et al. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood. 2005;106:2436–43.
30. Nguyen H, Ramana CV, Bayes J, Stark GR. Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J Biol Chem. 2001;276:33361–8.
31. Fang P, Hwa V, Rosenfeld RG. Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway. Exp Cell Res. 2006;312:1229–39.
32. El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, Kwiatkowski DJ. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. Cancer Res. 2004;64:3436–43.
33. Matsumoto K, Okano J, Murawaki Y. Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells. J Gastroenterol. 2005;40:722–32.

Oxidative Stress Induces Anti-Hepatitis C Virus Status via the Activation of Extracellular Signal-Regulated Kinase

Masahiko Yano,[1,3] Masanori Ikeda,[1] Ken-ichi Abe,[1] Yoshinari Kawai,[1,2] Misao Kuroki,[1] Kyoko Mori,[1] Hiromichi Dansako,[1] Yasuo Ariumi,[1] Shougo Ohkoshi,[3] Yutaka Aoyagi,[3] and Nobuyuki Kato[1]

Recently, we reported that β-carotene, vitamin D_2, and linoleic acid inhibited hepatitis C virus (HCV) RNA replication in hepatoma cells. Interestingly, in the course of the study, we found that the antioxidant vitamin E negated the anti-HCV activities of these nutrients. These results suggest that the oxidative stress caused by the three nutrients is involved in their anti-HCV activities. However, the molecular mechanism by which oxidative stress induces anti-HCV status remains unknown. Oxidative stress is also known to activate extracellular signal-regulated kinase (ERK). Therefore, we hypothesized that oxidative stress induces anti-HCV status via the mitogen activated protein kinase (MAPK)/ERK kinase (MEK)–ERK1/2 signaling pathway. In this study, we found that the MEK1/2-specific inhibitor U0126 abolished the anti-HCV activities of the three nutrients in a dose-dependent manner. Moreover, U0126 significantly attenuated the anti-HCV activities of polyunsaturated fatty acids, interferon-γ, and cyclosporine A, but not statins. We further demonstrated that, with the exception of the statins, all of these anti-HCV nutrients and reagents actually induced activation of the MEK–ERK1/2 signaling pathway, which was inhibited or reduced by treatment not only with U0126 but also with vitamin E. We also demonstrated that phosphorylation of ERK1/2 by cyclosporine A was attenuated with *N*-acetylcysteine treatment and led to the negation of inhibition of HCV RNA replication. We propose that a cellular process that follows ERK1/2 phosphorylation and is specific to oxidative stimulation might lead to down-regulation of HCV RNA replication. *Conclusion:* Our results demonstrate the involvement of the MEK–ERK1/2 signaling pathway in the anti-HCV status induced by oxidative stress in a broad range of anti-HCV reagents. This intracellular modulation is expected to be a therapeutic target for the suppression of HCV RNA replication. (HEPATOLOGY 2009;50: 678-688.)

Hepatitis C virus (HCV), which belongs to the family Flaviviridae, is a single-stranded positive-sense RNA virus of approximately 9.6 kb.[1,2] Persistent infection with HCV causes chronic hepatitis, which often leads to liver cirrhosis and hepatocellular carcinoma.[3] Therefore, HCV infection is a major health problem worldwide. Interferon (IFN)-based therapies, including the combination of pegylated IFN with ribavirin, are the current standard strategies for chronic hepatitis, but their sustained virological response rates are unsatisfactory.[4,5] There is thus an urgent need for novel partners with IFN or more effective reagents that may improve the sustained virological response rate.

Following the development in 1999 of a cell culture system to support efficient HCV RNA replication,[6] numerous studies have identified reagents that inhibit HCV RNA replication and enhance the effect of IFN treatment.[7-9] Some of these reagents are already available for clinical use. Previously, we also developed a genome-length HCV RNA (strain O of genotype 1b) replication system (OR6) with Renilla luciferase (RL) as a reporter in hepatoma cell lines.[10] Using this OR6 assay system, we found that mizoribine,[11] as an immunosuppressant, and

Abbreviations: AA, arachidonic acid; BC, β-carotene; CsA, cyclosporine A; CyPA, cyclophilin A; DHA, docosahexaenoic acid; DMSO, dimethyl sulfoxide; EGF, epidermal growth factor: EPA, eicosapentaenoic acid; ERK, extracellular signal-regulated kinase; FBS, fetal bovine serum; FLV, fluvastatin; HCV, hepatitis C virus; IFN, interferon; LA, linoleic acid: MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; NS5A, nonstructural 5A; PTV, pitavastatin; PUFA, polyunsaturated fatty acid; RL, renilla luciferase; ROS, reactive oxygen species; VD2, vitamin D_2; VE, vitamin E.

From the Departments of [1]Tumor Virology and [2]Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; and the [3]Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata City, Japan.

Received August 5, 2008; accepted April 8, 2009.

Supported by grants-in-aid for a third-term comprehensive 10-year strategy for cancer control and for research on hepatitis from the Ministry of Health, Labor, and Welfare of Japan. K. A. was supported by a Research Fellowship from the Japan Society for the Promotion of Science for Young Scientists.

Address reprint requests to: Masanori Ikeda, Department of Tumor Virology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. E-mail: maikeda@md.okayama-u.ac.jp; fax: (81)-86-235-7392.

Copyright © 2009 by the American Association for the Study of Liver Diseases.

Published online in Wiley InterScience (www.interscience.wiley.com).

DOI 10.1002/hep.23026

Potential conflicts of interest: Nothing to report.

Additional Supporting Information may be found in the online version of this article.